Shorter regimen for resistant TB could save $740 million a year

17 December 2022: An analysis yesterday by researchers with the TB Alliance, Stop TB Partnership, World Health Organization (WHO), and other groups estimates that the recently approved BPaLM/BPaL treatment regimen for drug-resistant tuberculosis (DR-TB) could save governments up to $740 million a year, enough to supply more than 400,000 people with almost a year's worth of DR-TB treatment.

Read More →

Review finds test antibiotics unreliable for diagnosing TB

May 20, 2020 -- New research by scientists from the United Kingdom and Africa suggests a long-standing practice of using antibiotics to test whether an individual may have tuberculosis (TB) is an unreliable method for diagnosing the disease.

Read More →

Industry urges more government action on antibiotic development

The level of funding for late-stage research and development of new antibiotics and other products to combat antimicrobial resistance (AMR) is insufficient to meet global health needs, and governments need to step up to the plate, according to an industry report released today (January 16).

Read More →

Page 1 of 1 · Total posts: 3